Repligen Executive Chair Tony Hunt to Retire; Dr. Martin D. Madaus Elected Chair

Core Viewpoint - Repligen Corporation has announced the election of Dr. Martin D. Madaus as Chair of the Board, effective March 13, 2026, following the retirement of Tony Hunt as Executive Chair [1][2] Group 1: Leadership Transition - Tony Hunt is retiring from his role as Executive Chair and member of the Board of Directors effective March 13, 2026, but will continue to serve as an advisor until March 2027 [1][2] - Dr. Martin D. Madaus, who has been a director since February 2023, has extensive industry experience, including leadership roles at Millipore Corporation [2][3] - Olivier Loeillot, President and CEO of Repligen, expressed confidence in the leadership transition, highlighting the strong foundation laid by Hunt and the qualifications of Madaus [2] Group 2: Company Overview - Repligen Corporation is a global life sciences company focused on developing and commercializing innovative bioprocessing technologies for the manufacturing of biological drugs [3] - The company serves biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide, with a focus on areas such as Filtration and Fluid Management, Chromatography, Process Analytics, and Proteins [3] - Repligen's headquarters are located in Waltham, Massachusetts, with manufacturing sites primarily in the U.S. and additional key locations in Estonia, France, Germany, Ireland, the Netherlands, and Sweden [3]